Year archive

Jacobio Pharmaceuticals Group Co., Ltd. — 2022 filings

All 37 regulatory filings released by Jacobio Pharmaceuticals Group Co., Ltd. (1167) in 2022, sourced directly from the official regulator.

37 Filings

2022 Period

2022 filings (37)

Filing	Released	Lang
TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE Remuneration Information	2022-12-28	English
VOLUNTARY ANNOUNCEMENT KRAS G12C INHIBITOR JAB-21822 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATIONS BY THE CENTER FOR DRUG EVALUATION (CDE) OF THE NMPA Regulatory Filings	2022-12-15	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2022 Share Issue/Capital Change	2022-12-02	English
VOLUNTARY ANNOUNCEMENT PRECLINICAL RESULTS OF KRAS G12C INHIBITOR IN COMBINATION WITH SHP2 INHIBITOR WILL BE PRESENTED AT THE ESMO ASIA CONGRESS 2022 Regulatory Filings	2022-12-01	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2022 Regulatory Filings	2022-11-01	English
VOLUNTARY ANNOUNCEMENT COLLABORATION WITH MERCK ON COMBINATION THERAPY OF JAB-21822 AND CETUXIMAB Regulatory Filings	2022-10-13	English
SUPPLEMENTAL ANNOUNCEMENT TO THE 2021 ANNUAL REPORT AND THE 2022 INTERIM REPORT Regulatory Filings	2022-10-06	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2022 Regulatory Filings	2022-10-03	English
2022 INTERIM REPORT Interim / Quarterly Report	2022-09-22	English
VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED CDE APPROVAL FOR THE PHASE II PIVOTAL STUDY OF KRAS G12C INHIBITOR JAB-21822 IN CHINA Regulatory Filings	2022-09-06	English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE I/IIa CLINICAL TRIAL OF JAB-BX102 FOR THE TREATMENT OF ADVANCED SOLID TUMOR IN CHINA Regulatory Filings	2022-09-02	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2022 Regulatory Filings	2022-09-02	English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED WITH JAB-21822 IN THE PHASE IIa TRIAL ON KRAS G12C AND STK11 CO-MUTATION Regulatory Filings	2022-09-01	English
CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES Board/Management Information	2022-08-24	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND CHANGE IN USE OF PROCEEDS Interim / Quarterly Report	2022-08-23	English
DATE OF BOARD MEETING Report Publication Announcement	2022-08-11	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2022 Share Issue/Capital Change	2022-08-02	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2022 Regulatory Filings	2022-07-05	English
VOLUNTARY ANNOUNCEMENT VOLUNTARY LOCK-UP UNDERTAKINGS BY CERTAIN SHAREHOLDERS Regulatory Filings	2022-06-30	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 8, 2022 Declaration of Voting Results & Voting Rights Announcements	2022-06-08	English
VOLUNTARY ANNOUNCEMENT PHASE I CLINICAL DATA OF KRAS G12C INHIBITOR JAB-21822 AT 2022 ASCO ANNUAL MEETING Regulatory Filings	2022-06-06	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2022 Regulatory Filings	2022-06-02	English
VOLUNTARY ANNOUNCEMENT PHASE I CLINICAL DATA OF KRAS G12C INHIBITOR JAB-21822 WILL BE PRESENTED AT THE 2022 ASCO ANNUAL MEETING Regulatory Filings	2022-05-27	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2022 Regulatory Filings	2022-05-04	English
FORM OF PROXY FOR THE 2022 ANNUAL GENERAL MEETING AGM Information	2022-04-25	English
NOTICE OF ANNUAL GENERAL MEETING AGM Information	2022-04-25	English
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING AGM Information	2022-04-25	English
2021 ANNUAL REPORT Annual Report	2022-04-25	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2022 Regulatory Filings	2022-04-06	English
VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG (IND) APPROVAL FOR CD73 mAb JAB-BX102 IN CHINA Regulatory Filings	2022-03-25	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Board/Management Information	2022-03-22	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021, RESIGNATION OF DIRECTORS, AND CHANGE IN THE COMPOSITION OF NOMINATION COMMITTEE Annual Report	2022-03-22	English
DATE OF BOARD MEETING Report Publication Announcement	2022-03-10	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February 2022 Regulatory Filings	2022-03-01	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2022 Regulatory Filings	2022-02-07	English
VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG (IND) APPROVAL FOR AURORA A INHIBITOR JAB-2485 IN THE UNITED STATES Regulatory Filings	2022-01-17	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2021 Regulatory Filings	2022-01-05	English